|
注册号: Registration number: |
ChiCTR2300072691 |
|
最近更新日期: Date of Last Refreshed on: |
2023-08-09 21:17:34 |
|
注册时间: Date of Registration: |
2023-06-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
直视内镜下逆行阑尾炎治疗术(D-ERAT)治疗急性单纯性阑尾炎疗效评价的前瞻性多中心随机对照研究 |
|
Public title: |
Direct vision-endoscopic retrograde appendicitis therapy (D-ERAT) for treatment of acute uncomplicated appendicitis: A prospective multicenter randomized clinical trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
直视内镜下逆行阑尾炎治疗术(D-ERAT)治疗急性单纯性阑尾炎疗效评价的前瞻性多中心随机对照研究 |
|
Scientific title: |
Direct vision-endoscopic retrograde appendicitis therapy (D-ERAT) for treatment of acute uncomplicated appendicitis: A prospective multicenter randomized clinical trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
詹珂 |
研究负责人: |
杨歆 |
|
Applicant: |
Ke Zhan |
Study leader: |
Xin Yang |
|
申请注册联系人电话: Applicant telephone: |
+86 134 5218 7880 |
研究负责人电话:
Study leader's |
+86 138 8377 5022 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhanke@cqmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
305307293@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
研究负责人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
|
Applicant address: |
1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
Study leader's address: |
1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-047-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属第一医院临床科研伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee of the First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-06-19 00:00:00 | ||
|
伦理委员会联系人: |
严青/戴安娜 |
||
|
Contact Name of the ethic committee: |
Qing Yan/Anna Dai |
||
|
伦理委员会联系地址: |
重庆医科大学附属第一医院5号楼A栋 |
||
|
Contact Address of the ethic committee: |
Building A, Building 5, the First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 8901 1876 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区袁家岗友谊路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-funding |
||||||||||||||||||||||
|
研究疾病: |
急性阑尾炎 |
||||||||||||||||||||||
|
Target disease: |
acute appendicitis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1. 评价直视内镜下逆行阑尾炎治疗术(D-ERAT)治疗急性单纯性阑尾炎的有效性及安全性,为其临床应用提供高等级循证医学证据。 2. 建立直视内镜下逆行阑尾炎治疗术(D-ERAT)的规范操作流程; |
||||||||||||||||||||||
|
Objectives of Study: |
1. To evaluate the effectiveness and safety of direct endoscopic retrograde appendicitis therapy (D-ERAT) for the treatment of acute uncomplicated appendicitis and to provide high-level evidence-based medical evidence for its clinical application. 2. To establish a standardized procedure for direct endoscopic retrograde appendicitis treatment (D-ERAT); |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 由非粪石原因所致急性单纯性阑尾炎,及伴有阑尾穿孔、腹腔脓肿、急性肠梗阻及急性弥漫性腹膜炎等表现的复杂性阑尾炎患者; 2. 同时合并其他急腹症或患有严重感染性、传播性疾病者; 3. 有肠镜检查或内镜下手术的禁忌症,例如:心肺等功能不全,无法耐受内镜检查者;休克或消化道穿孔的高危患者;凝血机制障碍及出血倾向患者;长期使用类固醇的患者; 4. 任何疾病晚期致预期寿命<6个月; 5. 怀孕期以及哺乳期妇女; 6. 综合评估难以配合者,如不愿意接受研究措施或有精神病史者; 7. 对泻剂、造影剂过敏者; 8. 具有炎症性结肠病病史者; 9. 已经纳入其它研究可能对本研究有影响的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with acute uncomplicated appendicitis due to non-appendicolith(s) causes and complex appendicitis with appendiceal perforation, abdominal abscess, acute intestinal obstruction, and acute diffuse peritonitis found preoperatively or intraoperatively; 2. Patients with severe infectious or widespread diseases or concurrent acute abdominal conditions; 3. Patients with contraindications to colonoscopy or endoscopic procedures, e.g. with cardiopulmonary and other insufficiencies to tolerate endoscopy; at high risk of shock or gastrointestinal perforation; with impaired coagulation mechanisms and bleeding tendencies; with long-term steroids;. 4. Any terminal illness with life expectancy less than 6 months; 5. Pregnant women or lactating women; 6. Patients who have difficulty cooperating through comprehensive assessment, such as those who refuse to accept research measures or who have a history of mental illness 7. Patients with laxative and contrast media allergies; 8. Patients with a previous history of inflammatory bowel disease (IBD); 9. Patients who have taken part in other studies that can affect the results of the present study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-07-01 00:00:00至 To 2024-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-07-01 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由组长单位重庆医科大学附属第一医院专业统计人员提前使用计算机随机生成的随机数字进行随机分组,受试者按照1:1比例被随机分配至实验组或对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Professional statisticians from Chongqing Medical University's First Affiliated Hospital used computer-generated random numbers to randomly group the subjects, and subjects were randomly assigned to either the experimental or control group in a 1:1 ratio. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲 |
|
Blinding: |
Single blind |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验结束后,通过中国临床试验注册中心公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the experiment, by Chinese Clinical Trial Registry Center |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例报告表(CRF) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use Case Record Form (CRF) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |